Skip to main content

Table 11 Statistical analysis of the descriptor used in the QSAR model

From: QSAR, molecular docking studies, ligand-based design and pharmacokinetic analysis on Maternal Embryonic Leucine Zipper Kinase (MELK) inhibitors as potential anti-triple-negative breast cancer (MDA-MB-231 cell line) drug compounds

  AATS6i ATSC8i GATS5s VR1_Dze C2SP3 VIF P value
AATS6i 1      2.077006 0.006999
ATSC8i 0.374295 1     1.272532 0.000162
GATS5s −0.65093 −0.3855 1    1.984035 3.01E−05
VR1_Dze 0.000492 −0.16932 0.0273 1   1.059332 0.000661
C2SP3 0.280075 0.185489 0.013492 −0.15324 1 1.226411 −4.6729